why choose us

First received: February 12, 2025

Clinical Trial: Real-world Outcomes of Patients With HER2+ Metastatic Breast Cancer After Treatment With Trastuzumab Deruxtecan

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: HER2-positive Breast Cancer

Study Type: OBSERVATIONAL


Official Title: Real-world Outcomes of Patients With HER2-positive (HER2+) Metastatic Breast Cancer (mBC) After Treatment With Trastuzumab Deruxtecan (T-DXd) in the United States

Brief Summary: This study will explore treatment patterns and clinical outcomes using the US-based Flatiron Health database to describe patients with HER2+ mBC who were previously treated with T-DXd to better characterize this population and inform internal decision making in this rapidly changing therapeutic landscape.

Read more